GEMCITABINE / PLATINUM VS. VINORELBINE- PLATINUM IN PATIENTS WITH ADVANCED NON- SMALL- CELL LUNG CANCER

Abstract

Background: A platinum- based doublets with a third- generation agents /Gemcitabine, Vinorelbine/ represent the standard first- line treatment for advanced patients with non- small- cell lung cancer /NSCLC/ and good performance status. Aim: The aim of this study was to evaluate the two commonly used newer platinum- based regimes in response rate and survival. Methods: In the period 2005- 2007 ninety- four inoperable patients with NSCLC entered the study. The treatment schedule consist of Gemcitabine 1250 mg/m2 day 1 and 8 and cis- Platinum 80 mg/m2 with hydratation day 1- 46 patients /arm GP/ and Vinorelbine 30 mg/m2 day 1 and 8 and cis- Platinum 80 mg/m2 with hydratation day 1- 48 patients /arm VP/, every 21 days. Results: Overall response rate was 39% for GP and 32% for VP. Median survival was 10,3 and 9,8 months respectively. Neutropenia was significantly higher in arm VP as was thrombocytopenia on the GP arm. Conclusions: That data suggest that both regimes remain reasonable choices for patients with advanced NSCLC with slight prevalence of GP.

Keywords

• Gemcitabine
• Vinorelbine
• Non- small- cell lung cancer
• Response rate
• Survival